INACTIVATED EMULSION VACCINE AGAINST FOOT-AND-MOUTH DISEASE OF TYPE A

FIELD: veterinary virology, biotechnology. ^ SUBSTANCE: the suggested vaccine contains avirulent and purified antigenic material out of strain A (Georgia) being homologous to infection agent 1999/N1721 obtained in passaged cell culture VNK-21 being the suspension that contains, predominantly, 146S a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MAMKOV NIKOLAJ STEPANOVICH, MIKHALISHIN VALERIJ VASIL'EVICH, MIKHALISHIN DMITRIJ VALER'EVICH, SHCHERBAKOV ALEKSEJ VLADIMIROVICH, LEZOVA TAT'JANA NIKOLAEVNA
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MAMKOV NIKOLAJ STEPANOVICH
MIKHALISHIN VALERIJ VASIL'EVICH
MIKHALISHIN DMITRIJ VALER'EVICH
SHCHERBAKOV ALEKSEJ VLADIMIROVICH
LEZOVA TAT'JANA NIKOLAEVNA
description FIELD: veterinary virology, biotechnology. ^ SUBSTANCE: the suggested vaccine contains avirulent and purified antigenic material out of strain A (Georgia) being homologous to infection agent 1999/N1721 obtained in passaged cell culture VNK-21 being the suspension that contains, predominantly, 146S and 75S immunogenic components of foot-and-mouth disease virus. Moreover, the vaccine contains maintenance medium and butyric adjuvant in efficient ratios. The strain has been deposited in collection of FGU VGNKI under registration number - industrial culture strain of foot-and-mouth disease virus A (Georgia) 1999/N1721-DEP of serotype A. As maintenance medium it is necessary to apply serum-free Earle's solution at addition of FGMS, GBCS and antibiotics at pH being 7.4-7.6. Out of butyric adjuvants the vaccine contains butyric adjuvant of the All-Russia Research Institute of Animal Protection (VNIIZZH) or butyric adjuvant of Montanide ISA-70 or Montanide ISA-260 marks by "Seppic" (France). The vaccine provides efficient protection against homologous infection agent circulating in Transcaucasian countries and those of Central Asia, Near and Middle East. ^ EFFECT: higher efficiency. ^ 11 cl, 1 dwg, 5 ex, 8 tbl
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_RU2294759C2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>RU2294759C2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_RU2294759C23</originalsourceid><addsrcrecordid>eNrjZHD19HN0DvEMcwxxdVFw9Q31Cfb091MIc3R29vRzVXB0d_T0Cw5RcPP3D9F19HPR9fUPDfFQcPEMdnUMdlXwd1MIiQwAKuNhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfFBoUZGlibmppbORsZEKAEAJMwrqg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>INACTIVATED EMULSION VACCINE AGAINST FOOT-AND-MOUTH DISEASE OF TYPE A</title><source>esp@cenet</source><creator>MAMKOV NIKOLAJ STEPANOVICH ; MIKHALISHIN VALERIJ VASIL'EVICH ; MIKHALISHIN DMITRIJ VALER'EVICH ; SHCHERBAKOV ALEKSEJ VLADIMIROVICH ; LEZOVA TAT'JANA NIKOLAEVNA</creator><creatorcontrib>MAMKOV NIKOLAJ STEPANOVICH ; MIKHALISHIN VALERIJ VASIL'EVICH ; MIKHALISHIN DMITRIJ VALER'EVICH ; SHCHERBAKOV ALEKSEJ VLADIMIROVICH ; LEZOVA TAT'JANA NIKOLAEVNA</creatorcontrib><description>FIELD: veterinary virology, biotechnology. ^ SUBSTANCE: the suggested vaccine contains avirulent and purified antigenic material out of strain A (Georgia) being homologous to infection agent 1999/N1721 obtained in passaged cell culture VNK-21 being the suspension that contains, predominantly, 146S and 75S immunogenic components of foot-and-mouth disease virus. Moreover, the vaccine contains maintenance medium and butyric adjuvant in efficient ratios. The strain has been deposited in collection of FGU VGNKI under registration number - industrial culture strain of foot-and-mouth disease virus A (Georgia) 1999/N1721-DEP of serotype A. As maintenance medium it is necessary to apply serum-free Earle's solution at addition of FGMS, GBCS and antibiotics at pH being 7.4-7.6. Out of butyric adjuvants the vaccine contains butyric adjuvant of the All-Russia Research Institute of Animal Protection (VNIIZZH) or butyric adjuvant of Montanide ISA-70 or Montanide ISA-260 marks by "Seppic" (France). The vaccine provides efficient protection against homologous infection agent circulating in Transcaucasian countries and those of Central Asia, Near and Middle East. ^ EFFECT: higher efficiency. ^ 11 cl, 1 dwg, 5 ex, 8 tbl</description><language>eng ; rus</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2007</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20070310&amp;DB=EPODOC&amp;CC=RU&amp;NR=2294759C2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76418</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20070310&amp;DB=EPODOC&amp;CC=RU&amp;NR=2294759C2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MAMKOV NIKOLAJ STEPANOVICH</creatorcontrib><creatorcontrib>MIKHALISHIN VALERIJ VASIL'EVICH</creatorcontrib><creatorcontrib>MIKHALISHIN DMITRIJ VALER'EVICH</creatorcontrib><creatorcontrib>SHCHERBAKOV ALEKSEJ VLADIMIROVICH</creatorcontrib><creatorcontrib>LEZOVA TAT'JANA NIKOLAEVNA</creatorcontrib><title>INACTIVATED EMULSION VACCINE AGAINST FOOT-AND-MOUTH DISEASE OF TYPE A</title><description>FIELD: veterinary virology, biotechnology. ^ SUBSTANCE: the suggested vaccine contains avirulent and purified antigenic material out of strain A (Georgia) being homologous to infection agent 1999/N1721 obtained in passaged cell culture VNK-21 being the suspension that contains, predominantly, 146S and 75S immunogenic components of foot-and-mouth disease virus. Moreover, the vaccine contains maintenance medium and butyric adjuvant in efficient ratios. The strain has been deposited in collection of FGU VGNKI under registration number - industrial culture strain of foot-and-mouth disease virus A (Georgia) 1999/N1721-DEP of serotype A. As maintenance medium it is necessary to apply serum-free Earle's solution at addition of FGMS, GBCS and antibiotics at pH being 7.4-7.6. Out of butyric adjuvants the vaccine contains butyric adjuvant of the All-Russia Research Institute of Animal Protection (VNIIZZH) or butyric adjuvant of Montanide ISA-70 or Montanide ISA-260 marks by "Seppic" (France). The vaccine provides efficient protection against homologous infection agent circulating in Transcaucasian countries and those of Central Asia, Near and Middle East. ^ EFFECT: higher efficiency. ^ 11 cl, 1 dwg, 5 ex, 8 tbl</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2007</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHD19HN0DvEMcwxxdVFw9Q31Cfb091MIc3R29vRzVXB0d_T0Cw5RcPP3D9F19HPR9fUPDfFQcPEMdnUMdlXwd1MIiQwAKuNhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfFBoUZGlibmppbORsZEKAEAJMwrqg</recordid><startdate>20070310</startdate><enddate>20070310</enddate><creator>MAMKOV NIKOLAJ STEPANOVICH</creator><creator>MIKHALISHIN VALERIJ VASIL'EVICH</creator><creator>MIKHALISHIN DMITRIJ VALER'EVICH</creator><creator>SHCHERBAKOV ALEKSEJ VLADIMIROVICH</creator><creator>LEZOVA TAT'JANA NIKOLAEVNA</creator><scope>EVB</scope></search><sort><creationdate>20070310</creationdate><title>INACTIVATED EMULSION VACCINE AGAINST FOOT-AND-MOUTH DISEASE OF TYPE A</title><author>MAMKOV NIKOLAJ STEPANOVICH ; MIKHALISHIN VALERIJ VASIL'EVICH ; MIKHALISHIN DMITRIJ VALER'EVICH ; SHCHERBAKOV ALEKSEJ VLADIMIROVICH ; LEZOVA TAT'JANA NIKOLAEVNA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_RU2294759C23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; rus</language><creationdate>2007</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MAMKOV NIKOLAJ STEPANOVICH</creatorcontrib><creatorcontrib>MIKHALISHIN VALERIJ VASIL'EVICH</creatorcontrib><creatorcontrib>MIKHALISHIN DMITRIJ VALER'EVICH</creatorcontrib><creatorcontrib>SHCHERBAKOV ALEKSEJ VLADIMIROVICH</creatorcontrib><creatorcontrib>LEZOVA TAT'JANA NIKOLAEVNA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MAMKOV NIKOLAJ STEPANOVICH</au><au>MIKHALISHIN VALERIJ VASIL'EVICH</au><au>MIKHALISHIN DMITRIJ VALER'EVICH</au><au>SHCHERBAKOV ALEKSEJ VLADIMIROVICH</au><au>LEZOVA TAT'JANA NIKOLAEVNA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>INACTIVATED EMULSION VACCINE AGAINST FOOT-AND-MOUTH DISEASE OF TYPE A</title><date>2007-03-10</date><risdate>2007</risdate><abstract>FIELD: veterinary virology, biotechnology. ^ SUBSTANCE: the suggested vaccine contains avirulent and purified antigenic material out of strain A (Georgia) being homologous to infection agent 1999/N1721 obtained in passaged cell culture VNK-21 being the suspension that contains, predominantly, 146S and 75S immunogenic components of foot-and-mouth disease virus. Moreover, the vaccine contains maintenance medium and butyric adjuvant in efficient ratios. The strain has been deposited in collection of FGU VGNKI under registration number - industrial culture strain of foot-and-mouth disease virus A (Georgia) 1999/N1721-DEP of serotype A. As maintenance medium it is necessary to apply serum-free Earle's solution at addition of FGMS, GBCS and antibiotics at pH being 7.4-7.6. Out of butyric adjuvants the vaccine contains butyric adjuvant of the All-Russia Research Institute of Animal Protection (VNIIZZH) or butyric adjuvant of Montanide ISA-70 or Montanide ISA-260 marks by "Seppic" (France). The vaccine provides efficient protection against homologous infection agent circulating in Transcaucasian countries and those of Central Asia, Near and Middle East. ^ EFFECT: higher efficiency. ^ 11 cl, 1 dwg, 5 ex, 8 tbl</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; rus
recordid cdi_epo_espacenet_RU2294759C2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title INACTIVATED EMULSION VACCINE AGAINST FOOT-AND-MOUTH DISEASE OF TYPE A
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T00%3A38%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MAMKOV%20NIKOLAJ%20STEPANOVICH&rft.date=2007-03-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ERU2294759C2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true